STOCKSCREENR

GHRS

NASDAQ

GH Research PLC

$20.53+1.37(+7.15%)Mkt Cap: $1.27B

Key Stats

Market Cap

$1.27B

P/E Ratio

-25.99

EPS

$-0.79

Dividend Yield

0.00%

52-Week Range

$9.46 — $24.66

Volume

111.43K

Avg Volume

224.20K

Beta

1.00

Price Alerts for GHRS

Get alerted when GHRS hits your target price.

$

Free — enter your email to get started

Valuation

P/E (TTM)

-25.99

Forward P/E

—

PEG Ratio

2.31

P/S (TTM)

0.00

P/B (TTM)

3.23

P/FCF

—

EV/EBITDA

—

EV/Sales

—

Financial Health

ROE (TTM)

-0.16%

ROA (TTM)

-0.17%

ROIC

—

Gross Margin

0.00%

Operating Margin

0.00%

Net Margin

—

Debt/Equity

0.00

Current Ratio

34.13

Growth

EPS Growth (YoY)

—

Revenue Growth (YoY)

—

EPS Growth (3Y)

-1.25%

EPS Growth (5Y)

-3.06%

Sales Growth (3Y)

+0.00%

Sales Growth (5Y)

+0.00%

EPS Est (This Year)

$-1.46

EPS Est (Next Year)

$-1.82

Dividends

Dividend Yield

—

Annual Dividend

—

Payout Ratio

—

Frequency

—

Ex-Dividend Date

—

Cash/Share

$4.53

Analyst Consensus

Price Target Range

$32.00$37.00$40.00
LowMedianHigh

Consensus Target: $36.50(77.8% upside)

Ownership

Institutional %

—

Inst. Net Change

—

Insider Net Shares (90d)

0

Outstanding Shares

62.03M

Float

44.85M

Free Float %

72.30%

About

Sector

Healthcare

Industry

Biotechnology

Country

IE

Exchange

NASDAQ

IPO Date

2021-06-25

Employees

50

CEO

Velichka Valcheva

Index Membership

—

Website

https://www.ghres.com

GH Research PLC (GHRS) is a healthcare company in the biotechnology industry listed on the NASDAQ. With a market capitalization of $1.27B, a P/E ratio of -25.99, GHRS is tracked by stockscreenr alongside 25,000+ other tickers. Use the free stock screener to compare GHRS against other stocks using dozens of fundamental and technical filters.

Similar Stocks

CYBN

Cybin Inc.

$8.28

+1.22%

$413.02M

ARMP

Armata Pharmaceuticals, Inc.

$9.98

+4.50%

$365.60M

CBIO

Crescent Biopharma, Inc.

$22.37

+6.83%

$616.45M

ZBIO

Zenas BioPharma, Inc.

$19.32

+10.09%

$862.50M

BHVN

Biohaven Ltd.

$9.59

+4.24%

$1.02B

ABUS

Arbutus Biopharma Corporation

$4.20

+1.69%

$827.15M

Frequently Asked Questions

What is GH Research PLC's P/E ratio?

GH Research PLC (GHRS) has a trailing twelve-month (TTM) P/E ratio of -25.99. This is below the market average, which may suggest the stock is undervalued or has lower growth expectations. The P/E ratio measures how much investors are willing to pay per dollar of earnings.

Does GH Research PLC pay a dividend?

No, GH Research PLC (GHRS) does not currently pay a regular dividend. The company may be reinvesting profits into growth, research, or debt reduction instead of returning cash to shareholders through dividends.

What is GH Research PLC's market cap?

GH Research PLC (GHRS) has a market capitalization of $1.27 billion, classifying it as a small-cap company. Market cap is calculated by multiplying the current share price by the total number of outstanding shares.